MX2013015409A - Diagnostico de la enfermedad de alzheimer. - Google Patents
Diagnostico de la enfermedad de alzheimer.Info
- Publication number
- MX2013015409A MX2013015409A MX2013015409A MX2013015409A MX2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A
- Authority
- MX
- Mexico
- Prior art keywords
- alzheimer
- disease
- diagnosis
- genes
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere al diagnóstico y monitoreo de la enfermedad de Alzheimer en el sujeto vivo. Más particularmente, la invención se refiere a métodos que implican la medición de la expresión genética diferencial en células no neuronales tomadas de sujetos humanos que se sospecha tienen la enfermedad de Alzheimer en donde los genes que se miden son los genes dentro de la vía de señalización mTOR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1112246.2A GB201112246D0 (en) | 2011-07-15 | 2011-07-15 | Diagnosis of alzheimer's disease |
PCT/GB2012/051693 WO2013011294A2 (en) | 2011-07-15 | 2012-07-16 | Diagnosis of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013015409A true MX2013015409A (es) | 2014-03-31 |
Family
ID=44586710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013015409A MX2013015409A (es) | 2011-07-15 | 2012-07-16 | Diagnostico de la enfermedad de alzheimer. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20140295425A1 (es) |
EP (1) | EP2732290B1 (es) |
JP (1) | JP2014521315A (es) |
KR (1) | KR20140064779A (es) |
CN (1) | CN103765218A (es) |
AU (1) | AU2012285561A1 (es) |
BR (1) | BR112014000637A2 (es) |
CA (1) | CA2840797A1 (es) |
GB (1) | GB201112246D0 (es) |
IL (1) | IL230441A0 (es) |
MX (1) | MX2013015409A (es) |
RU (1) | RU2014105558A (es) |
WO (1) | WO2013011294A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10718021B2 (en) * | 2014-05-28 | 2020-07-21 | Georgetown University | Genetic markers for memory loss |
CN105018484B (zh) * | 2015-07-31 | 2017-10-13 | 北京泱深生物信息技术有限公司 | Crtap基因及其表达产物作为阿尔茨海默病的诊治靶标 |
CN106018827B (zh) * | 2016-05-30 | 2018-01-16 | 深圳大学 | 一种阿尔茨海默症检测标志物及其检测方法 |
WO2018136702A1 (en) | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
KR102577154B1 (ko) * | 2017-03-31 | 2023-09-12 | 뉴로디아그노스틱스 엘엘씨 | 알츠하이머 질환에 대한 림프구-기반 PKCε 시험 |
AU2018250727A1 (en) | 2017-04-11 | 2019-10-31 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (HSD17B) family |
SE543211C2 (en) | 2017-06-29 | 2020-10-27 | Mabtech Production Ab | Method and system for analyzing Fluorospot assays |
KR20240125690A (ko) | 2017-10-11 | 2024-08-19 | 리제너론 파마슈티칼스 인코포레이티드 | Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해 |
CN115078570B (zh) * | 2022-05-30 | 2024-05-28 | 郑州大学第一附属医院 | Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
GB0106051D0 (en) * | 2001-03-12 | 2001-05-02 | Isis Innovation | Diagnostic screens for alzheimer's disease |
GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
WO2009105549A2 (en) * | 2008-02-19 | 2009-08-27 | Oncomethylome Sciences Sa | Detection and prognosis of lung cancer |
GB0912394D0 (en) * | 2009-07-16 | 2009-08-26 | Univ Birmingham | Screening methods |
-
2011
- 2011-07-15 GB GBGB1112246.2A patent/GB201112246D0/en not_active Ceased
-
2012
- 2012-07-16 RU RU2014105558/15A patent/RU2014105558A/ru unknown
- 2012-07-16 BR BR112014000637A patent/BR112014000637A2/pt not_active Application Discontinuation
- 2012-07-16 US US14/233,113 patent/US20140295425A1/en not_active Abandoned
- 2012-07-16 AU AU2012285561A patent/AU2012285561A1/en not_active Abandoned
- 2012-07-16 MX MX2013015409A patent/MX2013015409A/es not_active Application Discontinuation
- 2012-07-16 KR KR1020147003651A patent/KR20140064779A/ko not_active Application Discontinuation
- 2012-07-16 JP JP2014519634A patent/JP2014521315A/ja active Pending
- 2012-07-16 CA CA2840797A patent/CA2840797A1/en not_active Abandoned
- 2012-07-16 CN CN201280035133.1A patent/CN103765218A/zh active Pending
- 2012-07-16 EP EP12738590.4A patent/EP2732290B1/en not_active Not-in-force
- 2012-07-16 WO PCT/GB2012/051693 patent/WO2013011294A2/en active Application Filing
-
2014
- 2014-01-13 IL IL230441A patent/IL230441A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB201112246D0 (en) | 2011-08-31 |
IL230441A0 (en) | 2014-03-31 |
CA2840797A1 (en) | 2013-01-24 |
CN103765218A (zh) | 2014-04-30 |
KR20140064779A (ko) | 2014-05-28 |
EP2732290B1 (en) | 2016-05-25 |
US20140295425A1 (en) | 2014-10-02 |
AU2012285561A1 (en) | 2014-01-09 |
WO2013011294A2 (en) | 2013-01-24 |
EP2732290A2 (en) | 2014-05-21 |
BR112014000637A2 (pt) | 2017-06-13 |
WO2013011294A3 (en) | 2013-04-04 |
JP2014521315A (ja) | 2014-08-28 |
RU2014105558A (ru) | 2015-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013015409A (es) | Diagnostico de la enfermedad de alzheimer. | |
EP3498729A3 (en) | Therapeutic targets for alzheimer's disease | |
MX345230B (es) | Metodos para diagnosticar patogenos de enfermedad infecciosa y su sensibilidad a farmacos. | |
IL242842A (en) | Methods for detecting and diagnosing cardiac arrhythmias | |
CA2941917C (en) | Methods for the diagnosis and treatment of inflammatory bowel disease | |
HRP20130618T1 (en) | Methods of using mirna for detection of in vivo cell death | |
EP4219760A3 (en) | Methods, compositions, and devices utilizing microrna to determine physiological conditions | |
NZ796092A (en) | Methods for detecting signatures of disease or conditions in bodily fluids | |
EA201391154A2 (ru) | Способы и композиции для нацеливания на адипоциты у млекопитающих | |
BR112013001752A2 (pt) | método de detectar doenças ou condições usando células fagocídicas | |
MX2014016014A (es) | Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon. | |
MX2010001993A (es) | Metodos y composiciones para diagnosticar una enfermedad. | |
MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
MY148484A (en) | Caspase imaging probes | |
FR2991775B1 (fr) | Diagnostic multivarie de l'etat nutritionnel des cultures | |
IN2014DN08398A (es) | ||
WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
HK1213753A1 (zh) | 用於臨床試驗對象的疼痛的改進定量分析的訓練方法 | |
CR20130402A (es) | Unidad de interfaz y sistema de medición | |
IN2015DN02818A (es) | ||
SG194235A1 (en) | Methods of predicting the development of complement-mediated disease | |
EP2839281A4 (en) | COMPOSITIONS AND METHODS OF IDENTIFYING AND DIAGNOSIS OF SALT SENSITIVITY OF BLOOD PRESSURE | |
PT2526422T (pt) | Método de diagnóstico da doença de sjögren | |
Kirpinar et al. | Global assessment of functioning and associated factors in psychiatric inpatients: a retrospective study | |
RU2011119752A (ru) | Способ оценки безопасности введения наночастиц меди в организм |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |